發送短信 : Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in East Asian patients with stage IV squamous non-small cell lung cancer: A subgroup analysis of the phase 3, open-label, randomized SQUIRE study

  _____     _____               _____     ______  
 / ____||  |  ___||     ___    |  ___||  /_   _// 
/ //---`'  | ||__      /   ||  | ||__    `-| |,-  
\ \\___    | ||__     | [] ||  | ||__      | ||   
 \_____||  |_____||    \__ ||  |_____||    |_||   
  `----`   `-----`      -|_||  `-----`     `-`'   
                         `-`